 Corbus Pharmaceuticals NASDAQ:CRBPs stock had its buy rating reaffirmed by research analysts at Oppenheimer in a report released on Monday, AnalystRatings.com reports. They presently have a 28.00 target price on the biopharmaceutical companys stock. Oppenheimers price target would indicate a potential upside of 233.73 from the companys previous close. A number of other equities analysts ... 